Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

6.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.1K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.7K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Capsid-engineered AAV vector overcomes a key intracellular barrier and efficiently transduces spiral ganglion neurons in adult mice.

Molecular therapy. Advances·2026
Same author

Editorial: Community Series in Engineered Immune Cells in Cancer Immunotherapy (EICCI), volume II.

Frontiers in immunology·2026
Same author

Ex vivo long-term expansion of human hematopoietic stem and progenitor cells as a tool for modeling vector integration sites and clonality.

Journal of translational medicine·2026
Same author

SAGA-Q: Gene Expression Differences Enable Detection of Retroviral Vectors with Mutagenic Potential.

Human gene therapy·2026
Same author

Therapeutic antibody delivery: vector tools to boost efficacy and affordability.

Frontiers in immunology·2026
Same author

Improved Antitumor Activity of Interleukin-12-Secreting Chimeric Antigen Receptor T Cells Targeting CD176 across Different Carcinomas.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2026
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

Related Experiment Video

Updated: Feb 19, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Uncoupling the Oncogenic Engine.

Axel Schambach1,2,3, Juliane W Schott1,2, Michael A Morgan4,2

  • 1Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.

Cancer Research
|November 4, 2017
PubMed
Summary
This summary is machine-generated.

Targeting cancer cell metabolism and oncogenic signaling, particularly the RAS-ERK1/2 pathway, offers new therapeutic strategies. This review explores exploiting these connections for effective cancer treatment.

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

5.0K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K

Related Experiment Videos

Last Updated: Feb 19, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

5.0K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Activating RAS mutations and hyperactivated ERK1/2 signaling are common in human tumors.
  • Effective long-term therapies targeting the RAS-ERK1/2 pathway are limited.
  • Aberrant cancer cell metabolism is increasingly recognized as a hallmark of cancer.

Purpose of the Study:

  • To review the intricate connections between oncogenic signaling and cancer cell metabolism.
  • To explore how these links can be leveraged for novel molecular medicine approaches.
  • To highlight strategies for treating malignancies driven by RAS-ERK1/2 signaling.

Main Methods:

  • Literature review of oncogenic signaling pathways in cancer.
  • Analysis of metabolic alterations in cancer cells.
  • Integration of signaling and metabolism research for therapeutic insights.

Main Results:

  • Oncogenic signaling pathways profoundly influence cancer cell metabolism.
  • Metabolic reprogramming supports tumor growth and survival.
  • Targeting both signaling and metabolism may overcome therapeutic resistance.

Conclusions:

  • Inhibiting oncogenic signaling and correcting metabolic dysregulation are crucial for cancer cell elimination.
  • Exploiting the interplay between RAS-ERK1/2 signaling and metabolism presents promising therapeutic avenues.
  • Novel molecular medicine strategies should integrate targeting of both aberrant signaling and metabolic processes.